| Literature DB >> 24669314 |
Shelley E Keating1, Elizabeth A Machan1, Helen T O'Connor2, James A Gerofi3, Amanda Sainsbury3, Ian D Caterson3, Nathan A Johnson2.
Abstract
OBJECTIVE: The purpose of this study was to assess the effect of high intensity interval training (HIIT) versus continuous aerobic exercise training (CONT) or placebo (PLA) on body composition by randomized controlled design.Entities:
Mesh:
Year: 2014 PMID: 24669314 PMCID: PMC3942093 DOI: 10.1155/2014/834865
Source DB: PubMed Journal: J Obes ISSN: 2090-0708
Figure 1Flowchart showing the study process. M: male, F: female, HIIT: high intensity interval training, CONT: continuous aerobic exercise, PLA: placebo control group.
Description of exercise interventions.
| Week | Frequency | Intensity | Session duration | Total weekly training time (including warm-up and cooldown, min) | |
|---|---|---|---|---|---|
| Work : recovery | Intervals (number) | ||||
| HIIT | |||||
| 1 | 3 | 120% VO2peak: 30 W | 30 : 180 s | 4 | 60 |
| 2 | 3 | 120% VO2peak: 30 W | 30 : 120 s | 5 | 55.5 |
| 3 | 3 | 120% VO2peak: 30 W | 45 : 120 s | 5 | 59.25 |
| 4 | 3 | 120% VO2peak: 30 W | 45 : 120 s | 6 | 67.5 |
| 5–12 | 3 | 120% VO2peak: 30 W | 60 : 120 s | 6 | 72 |
| CONT | |||||
| 1 | 3 | 50% VO2peak | 30 min | 108 | |
| 2 | 3 | 60% VO2peak | 40 min | 138 | |
| 3 | 3 | 65% VO2peak | 45 min | 144 | |
| 4 | 3 | 65% VO2peak | 45 min | 144 | |
| 5–12 | 3 | 65% VO2peak | 45 min | 144 | |
HIIT: high intensity interval training; CONT: continuous aerobic exercise; W: watts; VO2peak: peak aerobic capacity.
Baseline participant characteristics.
| Characteristics | PLA ( | CONT ( | HIIT ( |
|---|---|---|---|
| Demographics | |||
| Age (years) | 42.9 (2.8) | 44.1 (1.9) | 41.8 (2.7) |
| Sex ( | 2/10 | 2/11 | 3/10 |
| BMI (kg/m2) | 28.2 (0.6) | 28.5 (0.6) | 28.2 (0.5) |
| Waist circumference (cm) | 90.9 (3.1) | 90.8 (2.1) | 92.4 (2.5) |
| Metabolic syndrome (Y/N) | 2/12 | 3/13 | 2/13 |
| Baseline habitual physical activity (Bouchard (kJ/Kg/day)) | 13.8 (0.6) | 13.7 (0.4) | 13.4 (0.3) |
Presented as mean (SE). PLA: placebo; CONT: continuous aerobic exercise; HIIT: high intensity interval training; M: male; F: female; BMI: body mass index.
Habitual energy intake and energy expenditure.
| PLA | CONT | HIIT |
| ||||
|---|---|---|---|---|---|---|---|
| Baseline | Postintervention | Baseline | Postintervention | Baseline | Postintervention | ||
| Energy intake | |||||||
| Fat (g/day) | 92 (11) | 78 (8) | 101 (12) | 87 (8) | 86 (11) | 79 (11) | 0.80 |
| % intake | 32 (3) | 30 (1) | 35 (2) | 34 (1) | 33 (3) | 33 (2) | 0.98 |
| Carbohydrate (g/day) | 265 (21) | 238 (14) | 268 (23) | 252 (22) | 227 (13) | 209 (20) | 0.28 |
| % intake | 43 (2) | 42 (2) | 43 (3) | 42 (2) | 41 (2) | 41 (2) | 0.80 |
| Protein (g/day) | 116 (10) | 111 (13) | 108 (10) | 98 (10) | 103 (11) | 95 (8) | 0.67 |
| % intake | 20 (1) | 20 (2) | 17 (1) | 18 (1) | 19 (1) | 19 (1) | 0.46 |
| Total energy intake (kJ/day) | 10319 (893) | 9283 (578) | 10523 (917) | 9527 (830) | 9403 (776) | 8190 (867) | 0.44 |
| Energy expenditure | |||||||
| Total energy expenditure (kJ/day) | 10354 (609) | 9990 (557) | 10527 (462) | 9989 (521) | 10414 (368) | 10506 (450) | 0.58 |
| Steps/day | 9897 (1271) | 7243 (1240) | 9740 (1036) | 8374 (956) | 9212 (820) | 8989 (890) | 0.42 |
| Sedentary time, <3 METS (hours/day) | 20:19 (0:58) | 18:57 (1:31) | 21:51 (0:11) | 20:54 (1:09) | 20:47 (0:41) | 21:27 (0:01) | 0.11 |
| Moderate activity, | 1:29 (0:13) | 1:17 (0:15) | 1:25 (0:12) | 1:13 (0:13) | 1:31 (0:07) | 1:41 (0:01) | 0.57 |
| Total self-reported energy expenditure (Bouchard score, kJ/Kg/day) | 13.8 (0.6) | 14.2 (0.8) | 13.7 (0.4) | 13.7 (0.4) | 13.4 (0.3) | 13.6 (0.4) | 0.79 |
Presented as mean (SE). PLA: placebo; CONT: continuous aerobic exercise; HIIT: high intensity interval training; METS: metabolic equivalents, n = 12/13/13 for PLA/CONT/HIIT, respectively, at baseline, n = 9/10/10 for PLA/CONT/HIIT, respectively, at postintervention testing for energy intake, n = 10/10/11 in PLA/CONT/HIIT, respectively, at postintervention testing for energy expenditure, and n = 9/10/10 in PLA/CONT/HIIT, respectively, at postintervention testing for total self-reported energy expenditure.
Outcome measures.
| PLA | CONT | HIIT |
| |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Post | Baseline | Post | ES (95% CI) | Baseline | Post | ES (95% CI) | ES (95% CI) HIIT versus CONT | ||
| Body composition (DEXA) | ||||||||||
| Trunk fat (g) Trunk fat (%) | 16562.1 (1203.6) 44.6 (2.3) | 17073.4 (1290.7) 45.6 (2.5) | 17337.5 (742.1) | 16627.8 (721.8) 44.2 (1.9) | −0.46 | 16142.5 (1153.2) 43.8 (1.5) | 15840.5 (1158.5) 43.5 (1.6) | 0.64 | −0.79 | 0.70 |
| Android fat (g) | 2724.0 (215.0) 48.2 (2.1) | 2874.5 (259.8) | 2884.5 (135.3) | 2736.3 (112.3) | −0.32 | 2791.2 (184.7) | 2736.6 (200.7) | 0.86 | −0.91 | 0.04** |
| Gynoid fat (g) | 5792.1 (306.9) | 5776.0 (321.3) | 6273.0 (375.3) | 6138.1 (424.1) | −0.59 | 5540.3 (391.2) | 5468.8 (442.9) | −0.34 | −0.28 | 0.28 |
| Total body fat (g) | 31432.8 (2064.9) | 32131.8 (2370.2) | 33134.1 (1669.6) | 32114.91 (184.0) | −0.64 | 30421.5 (2087.9) | 30229.1 (2408.9) | 0.22 | −0.73 | 0.049** |
| Total lean body mass (g) | 42374.8 (2892.6) | 42516.5 (3531.1) | 43637.8 (1873.8) | 44205.2 (2364.3) | 0.36 | 42211.6 (1360.7) | 42787.9 (1608.8) | 0.35 | 0.05 | 0.89 |
|
| ||||||||||
| Anthropometrics | ||||||||||
| Weight (kg) | 77.2 (3.5) | 78.6 (3.8) | 80.7 (1.5) | 79.9 (1.8) | −0.52 | 76.1 (2.7) | 76.3 (3.0) | 0.21 | −0.84 | 0.30 |
| Waist circumference (cm) | 90.9 (3.1) | 90.1 (3.2) | 90.8 (2.1) | 87.2 (1.7) | 0.24 | 92.4 (2.5) | 90.6 (2.5) | 0.27 | −0.05 | 0.76 |
| Hip circumference (cm) | 108.0 (1.6) | 108.8 (1.7) | 108.7 (1.4) | 107.5 (1.5) | 0.19 | 104.9 (2.1) | 106.2 (1.9) | 0.25 | −0.13 | 0.53 |
|
| ||||||||||
| Fitness | ||||||||||
| Work peak (W) | 114.4 (16.6) | 118.4 (17.5) | 128.8 (10.2) | 160.2 (12.3) | 1.41 | 134.7 (8.5) | 164.7 (10.8) | 1.17 | 0.49 | <0.001** |
| VO2peak (mL/kg/min)* | 22.3 (1.8) | 22.3 (1.7) | 24.0 (1.2) | 28.3 (1.5) | 1.63 | 25.3 (10.4) | 30.4 (1.4) | 1.76 | 0.23 | <0.001** |
|
| ||||||||||
| Biochemistry | ||||||||||
| AST (U/L) | 23.5 (2.4) | 18.7 (1.0) | 21.9 (2.1) | 20.1 (1.2) | −0.14 | 27.3 (3.9) | 22.5 (1.8) | −0.27 | 0.12 | 0.24 |
| ALT (U/L) | 26.7 (5.5) | 17.6 (2.5) | 22.0 (4.5) | 17.0 (1.8) | −0.12 | 36.7 (8.8) | 24.2 (4.8) | −0.23 | 0.08 | 0.22 |
| Fasting glucose (mmol/L) | 4.1 (0.2) | 4.3 (0.1) | 4.3 (0.1) | 4.4 (0.1) | −0.45 | 4.4 (0.2) | 4.3 (0.1) | −0.32 | −0.19 | 0.41 |
| Insulin (mU/L) | 7.3 (0.7) | 8.7 (1.2) | 8.6 (1.4) | 7.9 (1.1) | −0.39 | 8.0 (1.1) | 7.4 (0.7) | −0.47 | 0.12 | 0.31 |
| hs-CRP (mg/L) | 1.9 (0.4) | 1.7 (0.3) | 4.0 (1.6) | 2.9 (0.8) | −0.49 | 3.4 (0.8) | 3.6 (1.3) | −0.71 | 0.03 | 0.45 |
|
| ||||||||||
| Lipids | ||||||||||
| Total cholesterol (mmol/L) | 6.1 (0.2) | 5.4 (0.2) | 5.3 (0.3) | 5.5 (0.2) | −1.55 | 5.4 (0.3) | 5.4 (0.2) | −1.46 | 0.25 | 0.02** |
| HDL (mmol/L) | 1.6 (0.1) | 1.5 (0.1) | 1.4 (0.1) | 1.4 (0.1) | −0.21 | 1.7 (0.2) | 1.7 (0.2) | −0.59 | 0.46 | 0.20 |
| LDL (mmol/L) | 4.0 (0.1) | 3.4 (0.1) | 3.3 (0.3) | 3.6 (0.2) | −1.70 | 3.2 (0.2) | 3.2 (0.2) | −1.21 | −0.38 | 0.02** |
| Triglycerides (mmol/L) | 1.2 (0.1) | 1.1 (0.1) | 1.2 (0.2) | 1.1 (0.1) | −0.30 | 1.3 (0.1) | 1.3 (0.2) | −0.39 | 0.20 | 0.40 |
| Free fatty acids (umol/L) | 318.9 (34.5) | 484.6 (106.5) | 426.6 (42.0) | 460.6 (54.1) | −0.89 | 415.6 (47.9) | 493.8 (119.4) | −0.34 | −0.48 | 0.71 |
|
| ||||||||||
| Blood pressure | ||||||||||
| SBP (mmHg) | 117.7 (5.3) | 116.5 (4.7) | 122.8 (4.6) | 118.5 (3.2) | 0.32 | 116.2 (3.9) | 110.6 (3.2) | 0.81 | −0.27 | 0.10 |
| DBP (mmHg) | 74.3 (2.5) | 73.7 (2.8) | 78.4 (2.8) | 74.9 (2.5) | 1.00 | 76.8 (2.3) | 73.9 (2.4) | 0.61 | 0.25 | 0.13 |
Presented as Mean (SE). PLA: placebo; CONT: continuous aerobic exercise; HIIT: high intensity interval training; DEXA: dual-energy X-ray absorptiometry; VO2peak: peak aerobic capacity; AST: aspartate aminotransferase; ALT: alanine aminotransferase; hs-CRP: high sensitivity C-reactive protein; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; SBP: systolic blood pressure; DBP: diastolic blood pressure. *Estimated from W peak, n = 12/13/13 for PLA/CONT/HIIT, respectively, at baseline, 10/11/11 for PLA/CONT/HIIT, respectively, at postintervention testing for body composition (DEXA), and 11/11/11 for PLA/CONT/HIIT, respectively, at postintervention testing for anthropometrics, fitness, biochemistry, lipids, and blood pressure. **Significant group × time interaction (P < 0.05). ES: Hedge's bias corrected effect size; CI: confidence interval.
Figure 2Effect of 12 weeks of high intensity interval training (HIIT) or continuous aerobic exercise (CONT) or control (PLA) on relative percent change in (a) body mass, (b) total lean mass, and (c) total body fat. Circles show individual percentage change from baseline and horizontal bars show mean group percentage change from baseline. Values are means ± SE; n = 13 for HIIT, n = 13 for CONT, and n = 12 for PLA. †Significant treatment × time interaction (P < 0.05). *Significant difference between CONT and HIIT (P < 0.05).
Figure 3Effect of 12 weeks of high intensity interval training (HIIT) or continuous aerobic exercise (CONT) or control (PLA) on relative percent change in (a) trunk fat, (b) android fat, and (c) gynoid fat. Circles show individual percentage change from baseline and horizontal bars show mean group percentage change from baseline. Values are means ± SE; n = 13 for HIIT, n = 13 for CONT, and n = 12 for PLA. †Significant treatment × time interaction (P < 0.05). *Significant difference between CONT and HIIT (P < 0.05).